Day: July 23, 2025

health news

Qu Biologics Completes Enrolment of a Unique Study Testing a Novel Immunomodulator to Restore Immune Function in the Elderly

Staff July 23, 2025

VANCOUVER, British Columbia, July 23, 2025 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs),...

Read MoreRead more about Qu Biologics Completes Enrolment of a Unique Study Testing a Novel Immunomodulator to Restore Immune Function in the Elderly
health news

Ikena Oncology and Inmagene Biopharmaceuticals Announce Kristin Yarema, Ph.D., as Chief Executive Officer of Merged Company

Staff July 23, 2025

BOSTON and SAN DIEGO, July 23, 2025 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA) (“Ikena”) and Inmagene Biopharmaceuticals (“Inmagene”)...

Read MoreRead more about Ikena Oncology and Inmagene Biopharmaceuticals Announce Kristin Yarema, Ph.D., as Chief Executive Officer of Merged Company
health news

Ikena Oncology and Inmagene Biopharmaceuticals Announce Kristin Yarema, Ph.D., as Chief Executive Officer of Merged Company

Staff July 23, 2025

BOSTON and SAN DIEGO, July 23, 2025 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA) (“Ikena”) and Inmagene Biopharmaceuticals (“Inmagene”)...

Read MoreRead more about Ikena Oncology and Inmagene Biopharmaceuticals Announce Kristin Yarema, Ph.D., as Chief Executive Officer of Merged Company
health news

Akari Therapeutics Continues Key Research on its Novel Antibody Drug Conjugate Payload PH1 to Further Demonstrate its Unique Ability to Target Cancers Fueled by Oncogenic Drivers

Staff July 23, 2025

PH1 modulates RNA splicing, causing cancer cell death while activating the immune system to attack cancer throughout the body Company...

Read MoreRead more about Akari Therapeutics Continues Key Research on its Novel Antibody Drug Conjugate Payload PH1 to Further Demonstrate its Unique Ability to Target Cancers Fueled by Oncogenic Drivers
health news

Akari Therapeutics Continues Key Research on its Novel Antibody Drug Conjugate Payload PH1 to Further Demonstrate its Unique Ability to Target Cancers Fueled by Oncogenic Drivers

Staff July 23, 2025

PH1 modulates RNA splicing, causing cancer cell death while activating the immune system to attack cancer throughout the body Company...

Read MoreRead more about Akari Therapeutics Continues Key Research on its Novel Antibody Drug Conjugate Payload PH1 to Further Demonstrate its Unique Ability to Target Cancers Fueled by Oncogenic Drivers
health news

Alkeus Pharmaceuticals Announces Gildeuretinol Data Presentations During the American Society of Retina Specialists (ASRS) 43rd Annual Meeting July 29-August 2

Staff July 23, 2025

CAMBRIDGE, Mass., July 23, 2025 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to preserving the sight of...

Read MoreRead more about Alkeus Pharmaceuticals Announces Gildeuretinol Data Presentations During the American Society of Retina Specialists (ASRS) 43rd Annual Meeting July 29-August 2
health news

Alkeus Pharmaceuticals Announces Gildeuretinol Data Presentations During the American Society of Retina Specialists (ASRS) 43rd Annual Meeting July 29-August 2

Staff July 23, 2025

CAMBRIDGE, Mass., July 23, 2025 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to preserving the sight of...

Read MoreRead more about Alkeus Pharmaceuticals Announces Gildeuretinol Data Presentations During the American Society of Retina Specialists (ASRS) 43rd Annual Meeting July 29-August 2
health news

CORRECTING AND REPLACING – Safety Shot Announces Pricing of $10.6 Million Registered Direct Offering and Private Placement for Total Gross Proceeds of $16.3 Million.

Staff July 23, 2025

SCOTTSDALE, AZ, July 23, 2025 (GLOBE NEWSWIRE) -- In a release issued yesterday by Safety Shot, Inc. (Nasdaq: SHOT), please...

Read MoreRead more about CORRECTING AND REPLACING – Safety Shot Announces Pricing of $10.6 Million Registered Direct Offering and Private Placement for Total Gross Proceeds of $16.3 Million.
health news

Intelligent Bio Solutions to Strengthen FDA 510(k) Submission with New Positive Data Demonstrating Ultra-Precise Fingerprint Sweat Detection and Platform Resilience

Staff July 23, 2025

Data confirms Company’s ability to detect trace sweat volumes at ultra-micro level System demonstrates resilience across diverse conditions NEW YORK,...

Read MoreRead more about Intelligent Bio Solutions to Strengthen FDA 510(k) Submission with New Positive Data Demonstrating Ultra-Precise Fingerprint Sweat Detection and Platform Resilience
health news

CORRECTING AND REPLACING – Safety Shot Announces Pricing of $10.6 Million Registered Direct Offering and Private Placement for Total Gross Proceeds of $16.3 Million.

Staff July 23, 2025

SCOTTSDALE, AZ, July 23, 2025 (GLOBE NEWSWIRE) -- In a release issued yesterday by Safety Shot, Inc. (Nasdaq: SHOT), please...

Read MoreRead more about CORRECTING AND REPLACING – Safety Shot Announces Pricing of $10.6 Million Registered Direct Offering and Private Placement for Total Gross Proceeds of $16.3 Million.

You may have missed

health news

Atropos Health Expands Oncology Precision Medicine Capabilities with Publication of New AI Algorithms for Rare Disease and Integration of ASCO Guidelines

Staff December 5, 2025
health news

USF and Old Dominion to Play in the 2025 StaffDNA Cure Bowl

Staff December 5, 2025
health news

The Dot Corp Expands Services With New Promotional Products & Apparel Division

Staff December 5, 2025
health news

Vaniam Group Launches Predictive Pathways: A New Capability for Anticipating Market-Shaping Signals

Staff December 5, 2025
health news

Life Sciences BPO Market is expected to generate a revenue of USD 481.8 Billion by 2032, Globally, at 7.50% CAGR: Verified Market Research®

Staff December 5, 2025
error: Content is protected !!